Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GIST data sign a setback for Tasigna against Glivec as giant Novartis axes trial

This article was originally published in Scrip

Executive Summary

Novartis has discontinued a Phase III trial investigating its second generation BCR-ABL inhibitor, Tasigna (nilotinib), as a first-line treatment for gastrointestinal stromal tumours (GIST). The decision was based on the recommendation of an independent data monitoring committee and came after interim efficacy results suggested that the product is unlikely to show superiority over Glivec (Novartis' imatinib; Gleevec).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts